ILA Stock Overview
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections.
Island Pharmaceuticals Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.19|
|52 Week High||AU$0.29|
|52 Week Low||AU$0.12|
|1 Month Change||5.56%|
|3 Month Change||15.15%|
|1 Year Change||-29.63%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-63.81%|
Recent News & Updates
|ILA||AU Pharmaceuticals||AU Market|
Return vs Industry: ILA underperformed the Australian Pharmaceuticals industry which returned -26.2% over the past year.
Return vs Market: ILA underperformed the Australian Market which returned -2.2% over the past year.
|ILA Average Weekly Movement||20.5%|
|Pharmaceuticals Industry Average Movement||10.2%|
|Market Average Movement||8.9%|
|10% most volatile stocks in AU Market||15.9%|
|10% least volatile stocks in AU Market||4.1%|
Stable Share Price: ILA is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: ILA's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development.
Island Pharmaceuticals Limited Fundamentals Summary
|ILA fundamental statistics|
Is ILA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ILA income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.032|
|Net Profit Margin||0.00%|
How did ILA perform over the long term?See historical performance and comparison